EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is trading at $3.42, about ₹329 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 3.32% today. Indian residents can buy EyePoint Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$3.31
Today's high
$3.50
52 week low
$3.27
52 week high
$19.11
EYPT opened at $3.31, closed previously at $3.31, and has traded between $3.27 and $19.11 over the past 52 weeks.
About
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Key statistics
Avg. volume
3.08M
Market cap
$286.74M
P/E Ratio
-0.91
Price-to-sales ratio
102.81
Enterprise value
$1.26B
Free cash flow yield
-18.19%
Debt-to-equity ratio
0.13
Return on equity
-75.78%
ROIC
-73.99%
Beta
1.64
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$31.37M
Earnings per share
-$3.17
Free cash flow
-$243.39M
Net profit margin
-10994.73%
Gross margin
41.77%
EBITDA
-$229.34M
Revenue growth
-27.50%
Similar securities
This is not an investment recommendation
How to buy EyePoint Pharmaceuticals from India
Indian residents can buy EyePoint Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for EyePoint Pharmaceuticals and place an order
Find EyePoint Pharmaceuticals by name or by its ticker, EYPT, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. EyePoint Pharmaceuticals trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your EyePoint Pharmaceuticals position in USD and INR. EyePoint Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in EyePoint Pharmaceuticals from India
Trading and taxes when buying EyePoint Pharmaceuticals from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneEyePoint Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy EyePoint Pharmaceuticals stock?
Yes. EyePoint Pharmaceuticals (EYPT) has been listed on NASDAQ since 2005, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one EyePoint Pharmaceuticals share cost in rupees?
One EyePoint Pharmaceuticals share is $3.42 — about ₹329 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the EyePoint Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying EyePoint Pharmaceuticals from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of EyePoint Pharmaceuticals?
Yes. One EyePoint Pharmaceuticals share is $3.42, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in EyePoint Pharmaceuticals.
How are gains on EyePoint Pharmaceuticals shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the EyePoint Pharmaceuticals price. Paasa issues a capital-gains statement for your return.
Does EyePoint Pharmaceuticals pay a dividend?
No. EyePoint Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade EyePoint Pharmaceuticals from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on EyePoint Pharmaceuticals shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare EyePoint Pharmaceuticals shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your EyePoint Pharmaceuticals holding, its cost and its closing value.
How do I sell EyePoint Pharmaceuticals and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.